US 11,730,819 B2
Peptide derivatives having novel linkage structures
Daniel Teufel, Cambridge (GB); Gemma Mudd, Cambridge (GB); and Silvia Pavan, Cambridge (GB)
Assigned to BicycleTx Limited, Cambridge (GB)
Appl. No. 16/472,242
Filed by BicycleTx Limited, Cambridge (GB)
PCT Filed Dec. 20, 2017, PCT No. PCT/EP2017/083953
§ 371(c)(1), (2) Date Jun. 21, 2019,
PCT Pub. No. WO2018/115203, PCT Pub. Date Jun. 28, 2018.
Claims priority of application No. 1622140 (GB), filed on Dec. 23, 2016; and application No. 1713561 (GB), filed on Aug. 23, 2017.
Prior Publication US 2020/0316209 A1, Oct. 8, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/64 (2017.01); A61K 47/65 (2017.01); C07K 7/54 (2006.01)
CPC A61K 47/64 (2017.08) [A61K 47/65 (2017.08); C07K 7/54 (2013.01)] 23 Claims
 
1. A compound comprising a looped peptide structure attached via at least one alkylamino linkage to a molecular scaffold, wherein the looped peptide structure is a Bicycle structure comprising two peptide loops subtended between three linkages to the scaffold, a central linkage attached to the two peptide loops, wherein the molecular scaffold comprises a tris-substituted (hetero)aromatic or (hetero)alicyclic moiety, and wherein the looped peptide structure comprises a sequence:
(X)lA1(X)mA2(X)nA3(X)o;
or a pharmaceutically acceptable salt thereof,
wherein:
A1, A2 and A3 are selected from cysteine, Dap, N-AlkDap, or N-HAlkDap, provided that at least one of A1, A2 and A3 is Dap, N-AlkDap or N-HAlkDap, wherein each of A1, A2 and A3 attaches to the molecular scaffold via a thioether linkage or an alkylamino linkage;
X is any amino acid residue;
m is 3, 4, 5, 6, 7, 8 or 9;
n is 3, 4, 5, 6, 7, 8 or 9;
l is a number between 0 and 20; and
o is a number between 0 and 20.